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Abstract: According to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, 
posttraumatic stress disorder (PTSD) is characterized by three major symptom clusters following 
an event that elicited fear, helplessness, or horror. This review will examine each symptom 
cluster of PTSD separately, giving case study examples of patients who exhibit a preponderance 
of a given symptom domain. We use a translational approach in describing the underlying 
neurobiology that is relevant to particular symptoms and treatment options, thus showing 
how clinical practice can benefit from current research. By focusing on symptom clusters, we 
provide a more specific view of individual patient’s clinical presentations, in order to better 
address treatment needs. Finally, the review will also address potential genetic approaches to 
treatment as another form of individualized treatment.
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Introduction
Posttraumatic stress disorder (PTSD) is considered the fourth most common   psychiatric 
diagnosis, affecting 10% of all men and 18% of all women.1 In the aftermath of 
September 11th, 2001, in New York City, almost 57.8% of the population experienced 
at least one symptom of PTSD,2 whereas 11.2% developed full criteria for the   disorder.3 
The increased incidence of combat zones worldwide and the continued prevalence of 
violence in large urban centers in the United States enhance the   likelihood of exposure to 
traumatizing events during one’s lifetime. Combat-related PTSD is especially   pervasive: 
according to the National Vietnam Veterans Readjustment Study in 1988, 30.8% of 
male and 26.9% of female veterans suffered from PTSD at some point during their 
lives after combat.4 Many Vietnam theater veterans with PTSD have endured persistent 
social, medical, and psychological problems for close to 3 decades. Approximately 
two-thirds of the Vietnam veteran population has been divorced with an estimated 
one-fourth experiencing serious parenting problems. In addition to difficulties within 
family relationships, approximately 75% of Vietnam veterans with PTSD have abused 
or become dependent on alcohol in their lifetime, and an estimated 36% have been 
repeatedly arrested or incarcerated.4 In the current geopolitical climate, combat-related 
PTSD is a serious and global illness. The conflicts in Iraq and Afghanistan, although 
markedly different in many respects compared with the Vietnam theater of conflict (eg, 
improvised explosive devices, suicide bombings, urban warfare), have produced a large 
number of new PTSD cases, with early reports documenting a rate of 12.9% soldiers 
meeting strict criteria for PTSD and 18%   meeting more broadly defined criteria.5Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Of course, PTSD is not limited to veterans who   experience 
combat trauma. An increasing number of studies6–8 indicate 
that African Americans living in urban environments with 
low income are at, especially, high risk for both exposure 
to traumatic events and PTSD. For example, a recent study 
of 617 primary care patients (96% of whom were African 
Americans) found a 65% rate of lifetime trauma exposure and 
a 33% rate of PTSD.9 In such samples, exposure to trauma 
may begin early in life; studies of children and young adults 
from similar samples suggest that initial trauma exposure 
during childhood or adolescence is common.10 Studies of 
PTSD in civilian population have found a wide range of 
traumatic events that lead to the development of the disorder, 
such as motor vehicle accidents,11 sexual assault,12   including 
intimate-partner violence,13 and natural disasters, such as 
  hurricanes.14 In the aftermath of the recent earthquake in Haiti 
resulting in large-scale devastation and loss of life, we can 
expect a number of new cases of the disorder.15
According to the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition(DSM-IV),16 PTSD is charac-
terized by three major symptom clusters following an event 
that elicited fear, helplessness, or horror (shown in Figure 1). 
The first   category includes symptoms of traumatic events 
  reexperiencing, such as intrusive thoughts, nightmares, 
and flashbacks, and   phenomena that are often induced by 
reminders of the event. The second cluster is associated with 
avoidance of stimuli associated with the traumatic event, such 
as loss of interest in social interactions and detachment. The 
final category describes trauma-induced physiological altera-
tions, such as increased startle and hyperarousal including 
tachycardia, elevated perspiration, and shortness of breath. 
A new edition of the DSM, scheduled for publication in 
May 2013, will update the diagnostic criteria for PTSD. The 
proposed changes for DSM-5 include reorganizing the indi-
vidual symptoms into four broad categories; most notably, 
the current proposal is to separate avoidance symptoms and 
emotional numbing   symptoms into different clusters (see 
http://www.dsm5.org/ for proposed changes). However, the 
core symptoms will still remain in the diagnostic criteria for 
the disorder, thus the emphasis on individual symptoms rather 
than on the disorder as a whole is very timely. In fact, a recent 
paper by Shea and colleagues17 highlight the importance of 
Reexperiencing
symptoms
–  Intrusive/distressing thoughts
–  Recurrent bad nightmares
–  Experience flashbacks
–  Intense emotional upset at reminder
–  Intense physical reactions at reminder
–  Avoid thoughts/feelings
–  Avoid activities/situations/places
–  Can’t recall import aspects
–  Loss interest in activities
–  Detached/cut-off from others
–  Impaired range of emotions
–  Changed future plans/hopes
–  Difficulty sleeping
–  Irritable/anger outbursts
–  Difficulty concentrating
–  Overly alert
–  Jumpier/easily startled
Avoidance and
numbing
symptoms*
PTSD
Hyperarousal
symptoms
Figure 1 Diagram of PTSD symptoms broken down by the 3 diagnostic symptom clusters according to DSM-IV.
Note: *Proposed changes for DSM-V include separating avoidance and numbing symptoms into different clusters.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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treating patients who exhibit some but not all of the requisite 
PTSD symptoms across clusters for a full PTSD diagnosis 
(subsyndromal PTSD).
The heterogeneity of PTSD, by nature, implicates the 
involvement of several divergent neural systems in the 
underlying neurobiology of PTSD symptomatology;18 In 
addition, individual differences in one’s neurobiological 
makeup may also contribute to the variability observed in 
patient presentations following trauma exposure.19 Increasing 
our understanding of these neurobiological underpinnings 
can (1) greatly enhance our knowledge of the disease itself, 
(2) inform the development of novel treatments for PTSD 
symptom clusters, and (3) improve patient outcomes and 
prevent symptom relapse.
The heterogeneous expression of PTSD symptomatology 
may be strongly influenced by an individual’s autonomic 
response following trauma exposure; the output of the 
  autonomic nervous system can be indexed noninvasively 
via psychophysiological assessments of several peripheral 
targets, such as heart rate, blood pressure, skin conductance, 
  respiration rate, muscle contractions, and body temperature. 
Thus, these measurements provide a potential “objective” 
manner to assess PTSD symptom expression and   severity. 
Technological advances in the last decade have made such 
measurements possible using relatively simple methods 
at a reasonable cost and without extensive training in 
  psychophysiology. In other words, physiological indices can 
be easily obtained in most clinical settings and may prove ben-
eficial in the diagnosis and treatment evaluation of PTSD.
Several theorists20–22 have proposed that fear conditioning 
processes are involved in the etiology and maintenance 
of PTSD. As mentioned earlier, the DSM-IV diagnosis of 
PTSD requires exposure to a traumatic event and a cluster 
of symptoms associated with that event (eg, psychological 
and physiological reactions to trauma reminders and avoid-
ance of such reminders). This model suggests that through 
Pavlovian conditioning, neutral stimuli (conditioned stimuli 
[CSs]) that are temporally or spatially proximal to an aversive 
stimulus (unconditioned stimulus [US]) become associated 
and can elicit a conditioned fear response in the absence of 
the US. Thus, neutral stimuli (the CSs) present at the time of 
the trauma (the US) acquire the ability to elicit a conditioned 
fear reaction that can be triggered when the person subse-
quently encounters these or similar stimuli during the course 
of normal life. Consistent with this hypothesis, emotional and 
physiological reactivity to stimuli resembling the original 
traumatic event (even years after the event’s occurrence) is 
a prominent characteristic of PTSD and has been reliably 
replicated in the laboratory.23,24 Cognitive and behavioral 
avoidance strategies are further hypothesized to develop in 
an attempt to avoid or escape these distressing conditioned 
emotional reactions. One of the earliest theories proposed to 
explain avoidance   behavior is Mowrer’s 2-factor theory,25,26 
which posits that escape of a fear-conditioned stimulus nega-
tively reinforces avoidance behavior, thereby maintaining fear 
responses. Applied to PTSD, this theory suggests that avoid-
ance of reminders of the trauma can maintain the disorder 
by   preventing extinction of the original fear associations.27 
Finally, overgeneralization of trauma-related stimuli or situ-
ations (ie, an impaired ability to discriminate between danger 
and safety cues)28,29 can lead to hypervigilance and exagger-
ated startle responses that are part of the hyperarousal symp-
tom cluster. Data from our laboratory have shown that PTSD 
patients with high hyperarousal symptoms have the greatest 
difficulty in inhibiting fear responses to safety cues.29
Conceptualizing PTSD within the framework of fear con-
ditioning affords the use of laboratory paradigms, such as fear 
inhibition and fear extinction, to better understand altered fear 
processing and to develop better treatments for this dysregu-
lation. As mentioned earlier, most trauma   victims show fear 
and related reactions after a traumatic event, but these effects 
diminish over time in most   traumatized   individuals. We believe 
this reflects an intact ability to   extinguish learned fear and that 
the development of chronic PTSD in traumatized individuals 
who do not recover represents a failure of fear extinction. The 
inability to extinguish conditioned fear may be due to a com-
plex gene–environment interaction between one’s individual 
predisposition(s) and environmental factors, such as early life 
stress and the frequency, degree, and intensity of traumatic 
event(s). Several psychological models of PTSD have been 
proposed in the literature, including information-processing 
theory and emotional-processing theory (see Brewin and Hol-
mes30), that provides cognition-based theories of the   disorder.31 
However, fear conditioning offers a unique framework for 
translational studies, given that it can be modeled in animal 
experiments. Given the richness of the animal literature, the 
neural underpinnings of fear conditioning are well understood, 
and PTSD research can capitalize on these findings.32
The neurobiological model of fear dysregulation in 
PTSD suggests that responses to fearful stimuli can be 
so powerful that the cortical inputs are unable to inhibit 
amygdala   activity, as indicated by evidence of decreased 
prefrontal cortex (PFC) activity33 and increased amygdala 
activity34 during   presentations of traumatic imagery or 
  fear-evoking stimuli. Neuroimaging data collected during 
the last decade   demonstrate that PTSD patients appear to Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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have greater amygdala activation compared with controls 
(for a recent review, see Liberzon and Sripada35).Positron 
  emission tomography (PET) studies using combat scripts36 
and images33,37 and single-photon emission computed 
  tomography (SPECT) studies comparing responses to com-
bat sounds to white noise34 found greater levels of amygdala 
activation in PTSD patients. Furthermore, recent functional 
magnetic resonance imaging (fMRI) studies have found that 
  trauma-relevant words increase amygdala activation.38 This 
increased fear response extends beyond trauma-specific 
imagery: fearful faces also activate the amygdala in PTSD 
patients more than in controls.39,40 Exaggerated fear responses 
observed in PTSD may be due to a weakened inhibitory 
  control of the amygdala by the medial PFC (mPFC). PET 
studies of patients with PTSD show decreased anterior 
cingulate cortex (ACC, part of the PFC) activation to the 
emotional Stroop using fear-evoking words, such as “rape”;41 
however, PTSD patients have normal mPFC activation to 
nonemotional interference tasks.41,42 Weakened mPFC control 
of the amygdala may be a risk factor for psychopathology: a 
recent study of children with depressed parents found a lack 
of ACC activation to the emotional Stroop, using both fear-
relevant words depicting physical threat and social threat.43
The amygdala is an integral part of the neural circuit 
that controls fear responses and the peripheral targets of 
fear responses, such as those that can be measured using 
psychophysiological recordings.44 Figure 2 shows the neuro-
biological outputs that would be observed during dangerous 
conditions, such as those evoking “flight or fight” responses. 
The central nervous system responds with activation of the 
amygdala, which in turn activates   several loci of the peripheral 
nervous system, specifically the   sympathetic   nervous system 
via the lateral hypothalamus that increases sweat gland 
activity, measured by skin conductance levels (SCLs), and 
the parasympathetic nervous system (PNS) via the dorsal 
nucleus of the vagus increasing high-frequency heart-rate 
variability, measured by respiratory sinus   arrhythmia (RSA). 
In addition, the amygdala directly stimulates the pons, thus 
resulting in fear-potentiated startle responses. Therefore, 
arousal would be marked by increased SCL, decreased 
RSA, and heightened startle responses. On the other hand, 
during safe conditions, the mPFC suppresses amygdala 
activity via inhibitory connections between the two regions; 
a PTSD patient with a dysregulated fear system might show 
hyperarousal by displaying this physiological profile in less 
dangerous or safe situations. Another system that modulates 
arousal is the PNS, which operates through two vagal systems 
that originate in different brainstem nuclei;45 the myelinated 
vagus via the nucleus ambiguous is involved in resting states, 
reducing arousal during nonthreatening situations. However, 
in some individuals, the PNS can also be activated via the 
dorsal nucleus of the vagus, which is a more primitive, 
  unmyelinated vagal output; during extreme fear-evoking situ-
ations, this output can override the sympathetic activation via 
the ventrolateral periaqueductal gray.46 This type of response 
has been observed in dissociation45 and is associated with 
a decrease in SCL47 and an increase in RSA. Thus, PTSD 
patients exhibiting a more dissociative type symptomatology 
PONS Startle
Lat HYP
(SNS)
SCR
Dorsal nucleus
VAGUS
(PNS)
vlat PAG
SCR RSA AMY
PFC
Figure 2 Diagram of the neurobiology of fear responses. The amygdala is not drawn to scale.
Abbreviations: PFC, prefrontal cortex; AMY, amygdala; lat HYP, lateral hypothalamus; SNS, sympathetic nervous system; PNS, parasympathetic nervous system; SCR, skin 
conductance response; RSA, respiratory sinus arrhythmia; vlat PAG, ventrolateral periaqueductal gray.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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may have a different psychophysiological profile than those 
with greater hyperarousal symptoms.
Fear extinction involves a conditioning session in which 
a cue that was previously associated with danger is presented 
repeatedly without the US so that it no longer evokes the fear 
response. In the fear conditioning model of PTSD, extinction 
serves as a model for exposure-based therapy. Therefore, 
understanding the neurobiological bases of extinction is also 
of great importance to optimizing treatment. Neuroimaging 
studies using fear conditioning paradigms show that fear 
acquisition and extinction of fear also activate the PFC, spe-
cifically the ventromedial PFC (vmPFC).48 Similar studies 
with PTSD patients have found decreased vmPFC activation 
during fear extinction compared with traumatized controls.49 
Considerable neurochemical evidence also implicates the 
amygdala in the formation of extinction memories.
Several studies from the Davis lab have shown the role of 
N-methyl-D-aspartate (NMDA) receptors, as well as the MAP 
kinase second-messenger cascade in extinction memory.50–52 
Falls and colleagues51 first showed that NMDA antagonists 
dose-dependently block the acquisition of extinction learning. 
Others have confirmed that intra-amygdalar antagonists53 
impair extinction learning. D-cycloserine (DCS), an 
NMDA partial agonist, facilitates extinction learning when 
infused bilaterally within the basolateral amygdala prior to 
extinction.54 Notably, the intra-amygdala effect was as robust 
as the systemic drug effect, suggesting that the amygdala is 
the primary site of action.
This review will address each symptom cluster of PTSD 
separately while providing case studies from Operation 
Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) 
combat veterans with PTSD, who exhibit hallmark signs and 
symptoms within a given symptom domain. These clinical 
“snapshots” serve as real-life illustrations of the symptom 
presentations by patients and do not imply that those are 
the full extent of the patient’s symptom profile. Next, the 
potential neurobiological underpinnings of each symptom 
domain will then be discussed and optimal treatment 
strategies explored. The use of pharmacotherapies for the 
treatment of PTSD will be discussed in terms of drugs that 
have proven   effective at treating specific symptom clusters. 
However, for a full review of pharmacotherapy for PTSD, 
there are several recent reviews currently available.55–58 
A primary objective of this review is to highlight the need 
for more customized treatment regimens given (a) individual 
patient variability across the PTSD syndrome spectrum and 
(b) the increasing emergence of subsyndromal PTSD cases 
in which one or more symptom clusters (but not enough for 
a full PTSD diagnosis) are endorsed and cause significant 
distress and impairment.17
Treatment of full diagnostic PTSD
The current dogma related to psychiatric treatment of PTSD 
addresses the disorder as a whole and not with respect to 
individual symptom clusters. In the following sections, we 
will discuss treatment options that are most promising in 
targeting specific symptoms that may be applied to future 
therapeutic strategies. Existing treatments include forms of 
psychotherapy and psychopharmacology, treatments that 
are typically applied without consideration for individual 
symptom profiles.
The first-line, nonpharmacological treatment approach 
for PTSD has traditionally been psychological treatments, 
  including psychoeducation, individual psychotherapy, and 
group psychotherapy.59 Psychoeducation, which is not 
intended to be a stand-alone intervention, is designed to 
provide a patient with information regarding the nature and 
course of PTSD to a traumatized individual presenting with 
PTSD-related symptoms.59 Individual psychotherapy is aimed 
at specific PTSD symptom clusters and includes cognitive 
behavioral therapy (CBT) techniques, such as prolonged 
exposure (PE),60–62 and cognitive processing therapy (CPT).
PE therapy is widely regarded as an effective form 
of individual psychotherapy for PTSD.63–66 As described 
by Friedman,59 exposure to a traumatic event (Criterion 
A1) can produce a robust emotional response (Criterion 
A2), and this association can lead to PTSD avoidance 
symptoms through learning and conditioning paradigms. 
Avoidant behaviors become more frequent as a means of 
reducing the strong emotional responses to trauma-related 
stimuli. The primary purpose of CBT (including PE) is to 
deconstruct the PTSD-related aberrant thinking patterns 
that underlie avoidance. Effective PE techniques include 
imaginal and in vivo exposure to stimuli that are related to 
the traumatic event and a patient’s memories of this event.67 
Imaginal exposure therapy requires the patient to narrate their 
traumatic experience during weekly sessions that continue 
for 8–10 weeks, with patient’s distress level often assessed 
with the Subjective Units of Distress Scale (SUDS).65 An 
important step in imaginal exposure is for the patient to face 
contexts directly related to their traumatic experience during 
in vivo contact.60
The use of PE therapy has reportedly been limited in 
military populations because of a perceived stigma within 
military peer groups and the military leadership hierarchy.5 
Imaginal exposure therapy also requires intensive emotional Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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engagement in order to retrieve and activate fear memories. 
PTSD patients are often resistant to and avoidant of this 
level of engagement.68 For this reason, virtual reality (VR) 
can be presented as an attractive alternative to “stigmatized” 
talk therapy and imaginal exposure therapy, as well as an 
innovative means to reach avoidant PTSD patients. The 
use of immersive visual, tactile, and olfactory cues in a VR 
environment can reliably evoke fearful memories. VR has 
been successfully used for treatment of PTSD in 9/11 World 
Trade Center survivors69 and Vietnam veterans.62 Recent 
studies have demonstrated the validity of using VR70 and its 
success in treating combat veterans from OIF.71 Reger and 
colleagues70 presented 93 returning OIF veterans without 
PTSD with VR environments depicting an Iraqi cityscape and 
a desert convoy, two environments that are often experienced 
by military personnel serving tours in Iraq. In the Reger study, 
combat-exposed personnel rated both   environments as real-
istic representations of the actual scenarios into which they 
were deployed. This was a necessary first step in the dissemi-
nation and optimization of VR exposure therapies for treating 
cases of combat PTSD related to this theater of   conflict. Early 
case reports have indicated significant   symptom amelioration 
with a virtual Iraq treatment   environment.71 It is important to 
note that the recent cohort of returning veterans from OIF/
OEF may seek technological innovations such as VR for their 
PE treatment given that they were raised during an era in 
which video gaming is a popular pastime (see Figure 3).
CPT enables PTSD patients to focus on the cognitive and 
emotional aspects of their traumatic event through the written 
narratives detailing their experience.72 This is believed to help 
the patient better process and understand the raw emotions that 
have been altered by their own misinterpretations of the trau-
matic experience.65 Based on CPT theory, the ability to pro-
cess trauma-related natural and raw emotions, such as fear and 
melancholy, is blocked by patient-generated   negative belief 
systems. This blockade is often the result of a   preoccupation 
with overpowering emotions, including shame and guilt. CPT 
is aimed at helping the patient confront altered traumatic 
Full PTSD diagnosis or
clinically significant PTSD symptoms (subsyndromal)
Psychological treatments
– Psychoeducation
– Individual psychotherapy
Virtual reality exposure therapy
Problem: Avoidance or
patient desire for
technological Innovation
Problem: Refractory case with low
treatment response (future directions)
– Group therapy
TARGET: Reexperiencing, avoidance
– Serotonin-specific reuptake inhibitors
(SSRIs; eg, sertraline, paroxetine)
TARGET: Broad spectrum symptoms across
clusters
Pharmacological treatments
– Mood stabilizers (eg, lithium,
valproic acid)
TARGET: Hyper-arousal symptoms
– Anticonvulsants (eg, lamotrigine)
TARGET: SSRI-resistant avoidance
+/−
– Antipsychotics (eg, olanzapine)
TARGET: SSRI-resistant reexperiencing,
avoidance, and hyper-arousal
– Adrenergic inhibitors (eg, prazosin)
TARGET: Reexperiencing, (specifically
intrusive nightmares), hyper-arousal
(specifically insomnia)
– Externally generated multisensory
trauma cues to reduce avoidance
symptoms
TARGET: Reexperiencing
avoidance
Personalized treatment plan
– Genotyping for pharmacokinetic/
pharmacodynamic profile
– Genotyping for fear-related gene variants
– Cognitive behavioral therapy
(CBT; eg, prolonged
exposure, PE; cognitive processing
therapy, CPT)
TARGET: Broad spectrum symptoms
across clusters
Figure 3 PTSD treatment options spanning psychological and pharmacological measures. Upon full diagnosis of PTSD or clinically significant impairment on one or more 
PTSD symptom clusters without full diagnosis (subsyndromal), clinicians will typically begin a course of psychological treatments with or without concurrent pharmacological 
treatment. Pharmacological treatment is indicated in situations in which (1) the patient is receiving drug treatment, (2) there is a high degree of comorbid symptomatology 
(eg, major depression, panic disorder), and (3) full-scale CBT treatment is currently unavailable.59
Note: +/−, indicates in combination or as single-line treatment regimens; dashed line, indicates a future direction for PTSD patient care.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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memories while modifying negative belief systems (eg, “I 
am not powerless to face the dangers in my   environment.”). 
CPT has shown significant effectiveness in treating PTSD 
symptoms across clusters, equivalent to PE.73
At this point, it is important to note that many of the phar-
macological studies that have informed drug t  reatments for 
PTSD have significant limitations including small sample size 
and reduced power, a lack of double-blinding and random-
ization, and inconsistent dosing regimens.74 In fact, a recent 
report of the Institute of Medicine of the National Academies 
concluded that there was insufficient evidence to support 
efficacy of pharmacological treatment for PTSD.63 In spite of 
these limitations, several classes of drugs have been used in 
the treatment of symptoms of this disorder. Berger and col-
leagues56 recently reviewed the psychopharmacotherapies for 
treating PTSD that have evolved over the past two decades. 
Multiple drug classes, including antipsychotics, anticonvul-
sants, adrenergic-inhibitors, opioids, and benzodiazepines, 
were rated according to the empirical support behind their 
therapeutic value for treating PTSD. Berger and colleagues, 
using US Department of Health and Human Services 
Guidelines (1993), categorized the drug classes as follows: 
(1) level A, multiple double-blind, placebo-controlled trials 
with positive results (with level B criterion met); (2) level 
B, at least 1 double-blind, placebo-controlled trial with posi-
tive result (and level C criterion met); (3) level C, anecdotal 
reports, case studies, and open trials with   positive results 
and/or expert support; and (4) level D, few case reports 
with positive results and no expert support.75 Berger and 
colleagues found no drug classes meeting criteria for level A 
of evidence for use as a pharmacotherapy for PTSD. Of the 
remaining categorizations, five of the drugs studied by the 
Berger group were listed at level B, 7 at Level C, and 13 at 
level D. The most promising agents, determined to be level 
B by Berger and others, were risperidone and olanzapine 
(antipsychotics), valproic acid and lamotrigine (anticonvul-
sants), and prazosin (adrenergic inhibitor). The use of these 
drugs for treating specific PTSD symptom clusters will be 
discussed further below.
Reexperiencing (intrusive) 
symptoms
Clinical snapshots
A 28-year-old male combat veteran from OIF has nightmares 
6–7 times a week about combat experiences and thinks he 
is dying; he wakes up sweaty, upset, and confused, with 
hands locked. He experiences severe flashbacks 2–3 times 
a week and has daily intrusive thoughts. The patient reports 
panic attacks once a week and states, “Everywhere I look, 
I see Iraq”.
A 22-year-old male combat veteran reports military-
related dream content 1–2 times in the past week, and he 
also endorses waking up with “cold sweats”. He also states 
that when he lived with his wife, she used to comment that 
he thrashed around in his sleep 1–2 times per week. Patient 
endorsed having flashbacks twice per month, which are 
triggered when he encounters trash on the side of the road. 
Patient states, “The thing that I think about the most are the 
people that I knew that didn’t come back”.
A 29-year-old female veteran reports symptoms of PTSD 
related to childhood sexual abuse. She reports having intrusive 
thoughts about the experience, particularly when reminded 
by external stimuli (eg, a news story about molestation), and 
that these thoughts are distressing to her. She reports having 
occasional nightmares about her childhood sexual trauma.
Neurobiological underpinnings
PTSD symptoms falling into this cluster, which is focused on 
intrusive thoughts and reexperiencing the traumatic event, are 
among the most diagnostically “classic” symptoms of PTSD, 
in that they are most closely linked to the traumatic event. This 
does not, however, imply that these symptoms have the great-
est impact on patient reports of distress and impairment;17 
many patients report that avoidance and numbing symptoms 
cause the greatest degree of life impact.76,77 These symptoms 
will be discussed further below. Reexperiencing symptoms 
characteristically contain an exaggerated fear component. 
As described in the introduction, neuroimaging studies 
using trauma-relevant stimuli and psychophysiological 
reactivity tests using script-driven imagery have examined 
the biological bases of these symptoms. PET and fMRI 
studies using trauma reminders have shown limbic hyperac-
tivity in the amygdala.35 More peripheral measures of fear 
responding, such as skin conductance, heart-rate variability, 
and facial muscle contractions have also been measured 
during script-driven imagery studies. In a typical script-
driven imagery study, the participant describes an actual 
traumatic event from their combat experience. This event is 
then edited into a 30-second script that is read and recorded 
by the experimenter.24 The script is then played back to the 
participant while recording psychophysiological data that is 
then compared with physiological recordings during a rest-
ing period. This method has been used with many different 
PTSD populations: World War II veterans,78 Korean War 
veterans,78 Vietnam War veterans,79 Israeli War veterans,80 and 
Vietnam War combat nurses,81 in addition to sexual assault Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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victims.82 Among the trauma survivors observed across 
these studies, PTSD patients exhibited stronger heart rate 
and skin conductance responses to scripts than non-PTSD 
trauma survivors.
In 1998, Keane and colleagues83 published the largest 
study to date examining the utility of psychophysiological 
measures in diagnosing PTSD. The study was a multisite 
Department of Veterans Affairs Cooperative Study inves-
tigating 1,461 Vietnam War veterans using script-driven 
imagery and standardized combat images with psychophysi-
ological recordings. Although their study did not find a 
perfect correlation between interview-based PTSD diagnosis 
and psychophysiological reactivity, they did conclude that 
psychophysiological data provides useful and objective 
assessments of PTSD symptoms. It should be noted that the 
study could not conclude that psychophysiological assess-
ments would provide a clear diagnostic tool; however, the 
group differences speak to the underlying neurobiology of the 
disorder, as indexed by different physiological biomarkers.
Although exaggerated startle responses, in general, are 
characterized as hyperarousal symptoms, fear-potentiated 
startle, given its dependence on the amygdala,84 may be 
better described as a reexperiencing symptom. Using 
fear-potentiated startle methods with a population of Vietnam 
veterans with PTSD, our group found that higher current 
symptoms were associated with greater fear expression and 
impaired inhibition of fear.28 Data from our civilian PTSD 
cohorts recruited from a highly traumatized, low-income, 
inner-city population indicate that fear-potentiated startle 
is associated with intrusions and emotional and physical 
responses to trauma reminders (see Table 1). Impaired inhibi-
tion of fear-potentiated startle may be a specific biomarker 
for PTSD;29 which may be a vulnerability factor for the 
disorder or an acquired trait. Prospective studies using fear 
extinction prior to traumatization in civilian populations at 
high risk for trauma exposure have shown an association of 
impaired inhibition and PTSD symptoms after trauma.85,86 
Impaired fear inhibition to trauma stimuli is one of the 
common neuroimaging findings in PTSD.35 Recent stud-
ies have explored neural activation with regard to PTSD 
symptom clusters and have found   distinct neurobiological 
“subtypes.”18
In our urban trauma sample of 169 participants, 
  reexperiencing symptoms were positively correlated with 
RSA measured with spectral analysis of high-frequency 
heart-rate variability during fear condition. More specifically, 
flashback symptoms and physiological reactivity were posi-
tively associated with this measure of PNS control (Table 1). 
It is possible that reexperiencing symptoms are associated 
with exaggerated amygdala activity that may be reflected in 
differential vagal outputs via the nucleus ambiguous or the 
dorsal nucleus of the vagus (see Figure 2).
Treatment
In terms of pharmacological interventions for treating PTSD, 
the traditional approach has been to broadly address the 
symptoms of the disorder with a combination of benzodiaz-
epines or serotonin-selective reuptake inhibitors (SSRIs) and 
CBT. In fact, SSRIs (eg, sertraline, paroxetine) are widely 
recognized as the first-line treatment for PTSD.55,56 However, 
the need for enhanced development of pharmacotherapies 
for PTSD is evident in the consistently low response rates 
reported in addition to an observed lack of full remission in 
many patients.87,88 In addition, pharmacological treatment is 
indicated in situations in which (1) the patient is amenable to 
receiving drug treatment, (2) there is a high degree of comor-
bid symptomatology (eg, major depression, panic disorder), 
and (3) full-scale CBT treatment is currently unavailable.59
In many cases, a specific symptom cluster will dominate 
a patient’s clinical presentation and cause the highest degree 
of distress and functional impairment,89 either in individuals 
with a full diagnosis of PTSD or in trauma-exposed individu-
als who only endorse a subset of PTSD symptom clusters 
(subsyndromal PTSD). The treatment of subsyndromal PTSD, 
Table 1 Psychophysiological correlates of reexperiencing symptoms
Reexperiencing symptoms Response to danger cue
Startle (μV) RSA (HF-HRV)
Intrusive/distressing thoughts r = 0.28 P = 0.001** r = 0.14 P = 0.08
Recurrent bad nightmares r = 0.03 ns r = 0.11 ns
Experience flashbacks r = 0.08 ns r = 0.22 P = 0.005**
Intense emotional upset at reminder r = 0.17 P = 0.03* r = 0.13 P = 0.09
Intense physical reactions at reminder r = 0.16 P = 0.04* r = 0.15 P = 0.05*
Note: Startle and RSA data were collected during a fear-conditioning session. The symptoms (as assessed with the PSS) are correlated with responses during presentation 
of the danger cue, ie, the reinforced conditioned stimulus (CS+).
Abbreviations: RSA, respiratory sinus arrhythmia; HF-HRV, high-frequency heart-rate variability.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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as discussed by Shea et al17 is an important concern for clini-
cians in that PTSD symptoms that are under the criteria for a 
full PTSD diagnosis should be the focus of interventions as 
well. In many cases, it is possible to target specific symptom 
clusters when considering psychopharmacotherapy. A small 
number of drugs representing multiple classes have proven 
effective in treating the reexperiencing symptoms associated 
with PTSD. For example, the SSRIs fluoxetine and sertraline 
were shown to be effective in reducing intrusive thoughts 
and reexperiencing.90–92 In addition, the antipsychotics ris-
peridone and quetiapine (both as a primary treatment and as 
an adjunct)93–95 significantly decreased intrusive symptoms 
such as flashbacks in several clinical trials. Further, the 
anticonvulsant, carbamazepine,96 and the opioid receptor 
antagonists, naltrexone97 and nalmefene,98 have reduced reex-
periencing symptoms such as nightmares and flashbacks.
The recommendation for patients in whom reexperiencing 
symptoms are dominant in their psychiatric profile, evidence 
suggests the use of an SSRI as a first-line pharmacotherapy 
with the clinician having the option of altering the course of 
treatment to a different drug class if the patient proves to be a 
refractory PTSD case. A small number of studies have exam-
ined neuroanatomical changes in response to treatment. Two 
studies examined effects of SSRIs on hippocampal volume, 
a structure that is part of the limbic circuitry and closely 
connected to the amygdala. Both studies found that PTSD 
patients showed increased volume posttreatment, thereby 
eliminating pretreatment group differences in hippocampal 
size.99,100 On the other hand, psychotherapy does not appear 
to affect the volume of the hippocampus.101 Inasmuch as the 
limbic system is related to reexperiencing symptoms, these 
data suggest that SSRIs may be more effective in treating 
the underlying neurobiology of these symptoms.
Avoidance symptoms
Clinical snapshots
A 30-year-old male OIF/OEF combat veteran avoids 
thoughts or discussion about combat-related experiences, 
avoids reminders of combat, including military friends 
who remind him of combat and who may want to talk 
about combat experiences. The patient avoids activities 
that remind him of combat, even going so far as to quit a 
job in which the workplace smelled similar to the combat 
zone. The patient has difficulty connecting emotionally 
with others, although he reports previously being very 
social. Prior to combat exposure, he enjoyed exploring 
new places and things, but now he isolates and is fearful 
of new situations.
A 28-year-old female combat veteran does not have 
intrusive thoughts of her childhood sexual abuse or exposure 
to mortar blasts in Iraq and denies flashbacks or nightmares 
with traumatic content. She reports worsening of chronic social 
avoidance/isolation, avoidance of crowds, emotional numbing, 
and emotional detachment since returning from Iraq.
Neurobiological underpinnings
Although avoidance symptoms may not be as easily appar-
ent as reexperiencing or hyperarousal symptoms, they 
frequently contribute to long-term maintenance of PTSD. 
Avoidance of trauma reminders often includes avoidance 
of PTSD therapy, which may be especially pronounced with 
exposure-based psychotherapy. Furthermore, emotional 
numbing and detachment can reduce the number of patient 
opportunities to benefit from social support, a significant aid 
to recovery.102 Dissociation is frequently related to avoidance 
and detachment symptoms; this symptom profile differs to 
such an extent compared with other PTSD symptom profiles 
that these patients are sometimes classified as a “dissociative 
subtype”.103
Studies exploring the neurobiology of PTSD avoidance 
symptoms and related dissociation have yielded contradictory 
results. Avoidance symptoms appear to be associated with 
PNS activity. For example, PTSD patients who show 
a more dissociative response have decreased heart-rate 
changes during script-driven imagery104 in addition to dif-
ferent neurobiological activation in limbic and PFC areas.103 
  Furthermore, a study of sexual assault survivors with PTSD 
found that increased dissociation was related to reduced skin 
conductance responses.47 A large study of Vietnam veterans 
with dissociative symptoms, however, did not replicate 
physiological suppression.105 It appears as though the degree 
of traumatization contributes to the heterogeneity of psy-
chophysiological responses. A recent study by McTeague and 
colleagues found that PTSD patients who had experienced 
multiple traumas had lower skin conductance and startle 
responses to threat stimuli than PTSD patients who had a 
single traumatic event; multiple trauma PTSD patients also 
exhibited higher levels of avoidance and emotional numbing 
than single trauma victims.106
Preliminary data from a traumatized civilian population 
observed at Grady Hospital in urban Atlanta, which includes 
a significant number of patients with a history of polytrauma, 
support a negative relationship between avoidance symptom 
severity and skin conductance responses, indicating a signifi-
cant role of the PNS in this symptom domain. The notion of 
the PNS as a neurobiological substrate for PTSD avoidance Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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symptoms is supported by a positive correlation between 
avoidance symptoms and RSA, an index of PNS activity 
(see Table 2).107 Although avoidance and detachment were 
associated with physiological markers of fear, restricted range 
of emotion and memory impairment were not. The proposed 
revisions for the 5th edition of the DSM separate avoidance 
and emotional numbing into different clusters and will also 
expand the emotional numbing to include persistent negative 
emotions. Although it is possible that these two categories of 
symptoms have different neurobiological underpinnings, our 
data suggest that avoidance and detachment may be related. 
However, more data on the neurobiology of individual symp-
toms is needed before such conclusions can be made.
Treatment
The treatment recommendation for individuals who are 
predominantly avoidant is one of several CBT techniques 
including PE and CPT with the added caveat that individuals 
who continue to be avoidant in response to traditional CBT 
methods be given the opportunity to experience VR or other 
alternative measures. Emotional activation, which is one of 
the necessary components of effective exposure therapy,65 
may be hindered by numbing symptoms. As mentioned 
above, the next edition of the DSM may differentiate avoid-
ance and emotional numbing; future clinical studies of 
treatment efficacy may selectively target these symptoms.
As described earlier, a number of drug classes have been 
used to treat PTSD symptoms pharmacologically. The most 
effective pharmacotherapies to date have been antidepres-
sant SSRIs.89 It has been widely demonstrated that SSRIs 
are effective in reducing a number of PTSD symptoms 
across clusters;55 this includes several groups reporting a 
decrease in avoidant symptoms with the administration of 
the SSRIs fluoxetine,90 escitalopram,108 and sertraline.109 
The antipsychotic quetiapine94,110,111 and the mood stabilizer 
lamotrigine112 have shown some efficacy in ameliorating 
avoidant PTSD symptoms, but a preponderance of the 
empirical evidence supports the use of an SSRI coupled with 
a form of CBT and/or PE.
Hyperarousal symptoms
Clinical snapshots
A 31-year-old male combat veteran reports angry mood, 
exaggerated startle, daily intrusive memories, irritability, 
constant visual scanning of his environment, and worries 
about people “challenging” him when he goes out in public. 
This patient sometimes sleeps in his car because he feels more 
comfortable there and is better able to be alert. Patient states, 
“If I can control my anger I can go back to work.”
A 26-year-old male combat veteran reports anger, 
  irritability, and extreme emotional reactivity to triggers such 
as “people in his space.”
Neurobiological underpinnings
The hyperarousal symptoms of PTSD can often lead to more 
generalized impairments in function due to either sleep dis-
turbance or, more frequently, anger issues and subsequent 
occupational problems. As seen in the clinical snapshots 
above, anger is frequently reported as part of this symptom 
cluster. It is often a spouse or family members who encour-
ages a patient to seek treatment for these issues.
Despite the observations that exaggerated startle is a 
cardinal symptom of PTSD and sympathetic nervous system 
arousal can be easily measured with skin conductance, empir-
ical findings have not yielded consistent results. Most previ-
ous studies investigating PTSD-related exaggerated startle 
have found that baseline startle is only heightened within a 
relatively short time after a traumatic experience.113 On the 
other hand, elevated basal heart-rate has been observed in 
a number of studies with PTSD patients.114–116 This eleva-
tion appears to be related to the chronicity of the disorder, 
indicating greater cardiovascular risk for PTSD patients.114 
Table 2 Psychophysiological correlates of avoidance symptoms
Avoidance symptoms Response to danger cue
SCR (μs) RSA (HF-HRV)
Avoid thoughts/feelings r = −0.36 P = 0.0001*** r = 0.13 ns
Avoid activities/situations/places r = −0.25 P = 0.009** r = −0.16 ns
Can’t recall important aspects r = −0.09 ns r = 0.08 ns
Loss of interest in activities r = −0.30 P = 0.002** r = 0.52 P = 0.01*
Detached/cut-off from others r = −0.25 P = 0.01* r = 0.48 P = 0.02*
Impaired range of emotions r = −0.14 ns r = 0.21 ns
Changed future plans/hopes r = −0.23 P = 0.02* r = 0.09 ns
Note: SCR and RSA were collected during a fear-conditioning session. The symptoms (as assessed with the PSS) are correlated with responses during presentation of the 
danger cue, ie, the reinforced conditioned stimulus (CS+).
Abbreviations: SCR, skin conductance response; RSA, respiratory sinus arrhythmia; HF-HRV, high-frequency heart-rate variability.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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In our study of Croatian veterans, we found that those with 
PTSD had higher heart-rates of 10 beats per minute (bpm) 
on average than controls, even 10 years after their trauma.117 
These data suggest alterations in parasympathetic activity 
in addition to sympathetic system overactivation, which is 
likely to contribute to cardiovascular risk.115
Some hyperarousal symptoms, such as exaggerated 
  vigilance, may be associated with a poor ability to discrimi-
nate between danger and safety cues. As discussed previously, 
impaired inhibition of fear-potentiated startle to safety cues is 
associated with PTSD symptom severity in combat veterans.28 
In a recent study of a highly traumatized civilian population, 
we found that impaired fear inhibition was specific to PTSD 
rather than depression; moreover, PTSD subjects with the 
highest hyperarousal symptoms had the greatest impairment 
in fear inhibition29 (Table 3). Although other studies have not 
specifically focused on hyperarousal symptoms, heightened 
fear responses to safety cues (or overgeneralization of fear 
responses) have been frequently observed in PTSD sub-
jects.118 A recent fMRI study found that fear conditioning in 
PTSD subjects was associated with amygdala hyperactivity 
in response to the dangerous context and vmPFC hypoactivity 
to the safety context.49 Taken together, these data suggest that 
the reciprocal connections between the amygdala and PFC 
may underlie some hyperarousal symptoms. However, some 
neurobiological evidence points to broader brain structures 
associated with hyperarousal symptoms. One imaging study 
looked at regional cerebral blood flow in PTSD patients 
who presented with high levels of hyperarousal symptoms, 
including severe aggression and irritability, and found 
greater activation in the nucleus accumbens.119 A case study 
of a Croatian combat veteran with PTSD predominantly 
manifesting hyperarousal symptoms found that pretreatment 
hyperactivation of the amygdala and nucleus accumbens was 
normalized after a year of psychotherapy.120
Another line of evidence that relates to chronic 
  hyperarousal is diminished habituation in PTSD that may 
be a marker for hypervigilance. Habituation, like extinc-
tion, results in decreased responding to repeated stimula-
tion.121 Unlike extinction, however, habituation does not 
involve associative learning and is therefore not predicated 
on   fear-conditioning phenomena. Habituation is an evolu-
tionarily older mechanism and may not involve higher brain 
areas, such as the PFC or even the limbic system;121 deficits in 
habituation may be mediated by the autonomic system. Startle 
habituation deficits have been reported in Israeli patients who 
developed PTSD after trauma – the startle deficit was seen 
at an assessment of 4 months after trauma, indicating that it 
developed as part of the other PTSD symptoms.122 Our recent 
study of Croatian veterans with PTSD found that a higher 
proportion of PTSD subjects did not show linear habituation 
curves compared with controls.117
Treatment
As illustrated in Figure 1, hyperarousal symptoms of PTSD 
include sleep disturbances, anger and irritability, and explo-
sive behaviors. From a psychopharmacological perspective, 
a number of drug treatments have been explored as a means 
of reducing hyperarousal. Similar to the previously discussed 
symptom clusters, SSRIs such as fluoxetine,91 escitalopram,108 
and sertraline109 have shown significant efficacy in reducing 
hyperarousal symptoms. The mood stabilizers lithium123 and 
valproic acid,124 as well as the antipsychotic olanzapine125 have 
also been reported to decrease hyperarousal with the latter hav-
ing a profound effect on sleep disturbances. Furthermore, α-1 
adrenergic receptors have been implicated in PTSD-related 
sleep disturbances and hypervigilance.126 Based on the find-
ings of randomized clinical trials,126–128 open label studies,129–131 
and case reports,132,133 prazosin appears to be a reliable adjunct 
treatment for PTSD with specific benefits for ameliorating 
nightmares. Thus, the recommendation for patients present-
ing with these symptoms is to prescribe hypnotics or atypical 
antipsychotics for insomnia or prazosin for nightmares.
Tailoring individual treatment plans 
for PTSD: future directions
Future treatment strategies for combat-related PTSD may 
be governed by a shift toward personalized medicine. The 
  identification of particular environmental risk factors, geno-
types, or gene expression patterns specific to trauma exposure 
and PTSD may dictate which treatment regimens will be most 
effective for a particular patient. An area of increasing inter-
est to mental health clinicians is pharmacogenetics in which 
Table 3 Psychophysiological correlates of hyperarousal symptoms
Hyperarousal  
symptoms
Response to safety cue
Startle (μV) RSA (HF-HRV)
Difficulty sleeping r = 0.06 ns r = 0.08 ns
Irritable/anger outbursts r = 0.04 ns r = 0.47 P = 0.03*
Difficulty concentrating r = 0.23 P = 0.03* r = 0.47 P = 0.03*
Overly alert r = 0.18 ns r = 0.37 ns
Jumpier/easily startled r = 0.22 P = 0.04* r = 0.38 ns
Note:  Startle  and RSA  data were  collected  during  a  fear  conditioning  session. 
The symptoms (as assessed with the PSS) are correlated with responses during 
presentation of the safety cue, ie, the nonreinforced conditioned stimulus (CS−). 
Abbreviations: RSA, respiratory sinus arrhythmia; HF-HRV, high frequency heart-
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the goal is to genotype patients before starting a particular 
psychiatric pharmacological therapy as a means of determin-
ing a patient’s likelihood of a therapeutic response,134 Further, 
the identification of potential genetic variants that increase 
susceptibility for developing psychiatric illness would be a 
particularly important tool for advancing treatment options 
for PTSD and related anxiety disorders.
An example of such a variant may exist in the gene that 
codes for the serotonin transporter (5-HTT); a transmembrane, 
presynaptic protein that mediates the reuptake of serotonin 
from the synaptic cleft following transmitter release. A genetic 
polymorphism has been identified in humans containing a 44-bp 
deletion in the promoter region (frequently termed the short or 
S allele) that reduces transcription of the gene, translation of 
the messenger RNA, and 5-HTT expression on the presynaptic 
membrane.135–138 The 5-HTT “S ” allele was recently linked 
to a predisposition for the development of PTSD following a 
traumatic event. For example, in a gene–environment study of 
Hurricane Katrina victims, those individuals who possessed 
the “S ” allele and had low levels of social support were more 
likely to develop PTSD and major depression.139 A review of the 
genetics of PTSD is beyond the scope of this review, and there 
are several reviews currently available in the literature.140–142
There are a small number of genetic variants and envi-
ronmental interactions with strong empirical evidence for 
influencing the development of PTSD and with the greatest 
potential for impacting future therapeutic approaches to 
combat-related PTSD. Environmental factors that appear to 
have a strong influence on the development of PTSD after a 
traumatic event include one’s experiences during childhood, 
as well as one’s social support network after a traumatic event. 
Genetic variants that appear to influence an individual’s risk 
for PTSD after trauma include genes related to the hypotha-
lamic–pituitary–adrenal axis, the ascending brainstem locus 
coeruleus–noradrenergic system, and the limbic amygdalar 
frontal pathway that mediates fear processing.141,143–145 Within 
the latter neural systems, the serotonin, dopamine, glucocor-
ticoid receptor, γ-aminobutyric acid, apolipoprotein, brain-
derived neurotrophic factor, and neuropeptide Y systems have 
all been implicated in the genetic contribution to PTSD onset 
following a traumatic event.
An accumulating body of evidence suggests that PTSD 
is the result of complex gene–environment interactions. For 
example, as part of the largest genetic study of PTSD to date, 
Binder and colleagues146 studied the relationship between 
FKBP5 polymorphisms and past child abuse on one’s suscep-
tibility to developing PTSD. FKBP5 is a cochaperone protein 
that interacts with heat shock protein 90, a molecular chaper-
one itself, that maintains neuronal viability and binds to the 
glucocorticoid receptor.147 Four single nucleotide polymor-
phisms (SNPs) of the FKBP5 gene (rs9296158, rs3800373, 
rs1360780, and rs9470080) significantly interacted with 
child abuse severity (as measured by the traumatic events 
inventory) to predict adult PTSD symptoms (as measured 
by the PTSD Symptom Scale).
It is important to note that the extant gene–environment 
investigations of PTSD have examined the relationship 
between environmental factors (eg, social support) and either 
a DSM-IV diagnosis of PTSD or the overall clinical presenta-
tion of PTSD (eg, total PSS or Clinician Administered PTSD 
Scale score). There have been no studies, to our knowledge, 
that have investigated gene–environment relationships to 
specific symptom clusters. This is an intriguing area for 
future research efforts.
Novel pharmacological approaches that enhance fear 
extinction are currently being tested. The use of D-cyclos-
erine, a partial NMDA receptor agonist, as a treatment for 
PTSD arose as a result of numerous preclinical studies 
implicating NMDA glutamate receptor activity in learning 
and memory processes.148–151 Researchers administered DCS 
to rats immediately before extinction training and then sub-
sequently found greater extinction retention 24 hours later.152 
As mentioned earlier, an important aspect of fear learning 
of concern to clinicians is the return of fear following expo-
sure therapy (extinction training). DCS, in addition to its 
enhancement of extinction retention, has also been shown 
to reduce reinstatement of fear in rats.153 Barbara Rothbaum 
and her collaborators at Emory University recently inves-
tigated the use of DCS in combination with VR exposure 
(VRE) therapy for the fear of heights.154 After treatment, 
those patients who received DCS in combination with VRE 
showed significantly greater improvement compared with 
those who received placebo and VRE. Importantly, patients 
experienced a generalization of reduced fear of heights that 
extended beyond the virtual elevator context into “real world” 
contexts. DCS is currently being investigated as adjunct to 
exposure therapy in PTSD.
Recent studies have identified CB1 cannabinoid receptors 
as a potential therapeutic target for drug treatment in humans 
based on the finding that CB1 agonist administration has been 
shown to facilitate extinction in rats and mice.155 As putative 
drugs acting on the CB1 receptor and cannabinoid reuptake pro-
cesses are developed, this potential avenue of pharmacotherapy 
will be further explored. As seen from the above studies, these 
exploratory new drugs have the potential to enhance extinction 
learning during exposure sessions and to prevent relapse of Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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symptoms following the cessation of exposure therapy. Given 
that these drugs enhance fear inhibition, they may reduce both 
reexperiencing and hyperarousal symptoms.
It seems likely that the future treatment of PTSD will 
encompass highly individualized treatment in which an 
individual’s risk for developing PTSD prior to trauma 
  exposure (eg, during predeployment training), as well as his 
or her likelihood of responding well to pharmacological and 
behavioral therapies, is assessed across multiple dimensions 
including environmental, genetic, and psychophysiological. 
Consideration of genetic risk factors, as well as individual 
variability in clinical presentation across the different PTSD 
symptom clusters, will allow for treatment strategies tailored 
to each individual patient, resulting in greater treatment effi-
cacy and improved quality of life for PTSD patients.
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